Rifaximin for maintenance therapy in antibiotic-dependent pouchitis by Shen, Bo et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
Rifaximin for maintenance therapy in antibiotic-dependent 
pouchitis
Bo Shen*, Feza H Remzi, A Rocio Lopez and Elaine Queener
Address: The Pouchitis Clinic, Digestive Disease Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
Email: Bo Shen* - shenb@ccf.org; Feza H Remzi - remzif@ccf.org; A Rocio Lopez - lopezr@ccf.org; Elaine Queener - queenee@ccf.org
* Corresponding author    
Abstract
Background:  Pouchitis is the most common long-term complication of in patients with
restorative proctocolectomy and ileal pouch-anal anastomosis. Patients often develop antibiotic-
dependent form of pouchitis requiring long-term antibiotic therapy for remission maintenance.
Rifaximin, an oral, non-systemic, broad-spectrum antibiotic with a favorable safety profile, may be
a promising candidate agent for maintenance therapy. This historical cohort open-label study
investigated the efficacy and tolerability of rifaximin in maintaining symptomatic and endoscopic
remission in patients with antibiotic-dependent pouchitis.
Methods: Adult patients with antibiotic-dependent pouchitis received a 2-week course of various
antibiotics for induction of remission. Patients in remission then began maintenance therapy with
rifaximin 200 mg/day (to 1800 mg/day) for up to 24 months. Pouchitis Disease Activity Index
symptom scores were assessed every 1–3 months to evaluate efficacy.
Results: Fifty-one patients began maintenance therapy with rifaximin (median dose 200 mg/day);
33 (65%) maintained remission through 3 months (primary endpoint). Of these 33 patients, 26
(79%) successfully continued maintenance for 6 months after beginning maintenance, 19 (58%)
successfully continued for 12 months, and two (6%) successfully continued for 24 months. Only
one patient reported an adverse event (transient facial rash).
Conclusion: Patients' response to rifaximin as a maintenance therapy appears to be favorable in
this open-labeled trial of antibiotic-dependent pouchitis. Randomized, placebo-controlled trials
with a longer follow-up are warranted.
Background
Restorative proctocolectomy with ileal pouch-anal anas-
tomosis (IPAA) is the preferred surgical treatment for
patients with medically refractory ulcerative colitis (UC),
UC with dysplasia or cancer, and familial adenomatous
polyposis (FAP). Pouchitis, an idiopathic inflammation
of the ileal pouch frequently characterized by increased
number of loose bowel movements, urgency, and abdom-
inal cramping, is the most common long-term complica-
tion of IPAA. [1,2] Up to 50% of patients who undergo
IPAA for UC experience at least one episode of pouchitis,
whereas few patients (approximately 6%) who undergo
IPAA for FAP develop pouchitis. [3-5] The etiology of pou-
chitis is not well understood but likely involves altera-
tions in luminal bacteria (e.g., bacterial overgrowth) and
subsequent dysregulation of inflammatory responses in
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genetically susceptible patients. [1,3,6] The efficacy of
antibiotics and probiotics in treating pouchitis provides
additional evidence supporting the role of bacterial alter-
ations in the pathophysiology of this condition. [1,7]
Although many patients with pouchitis experience acute
episodes with remission and relapse, up to 17% develop
chronic disease that requires long-term therapy for treat-
ment or maintenance. [3,5,8-10] Acute or chronic types of
pouchitis can usually be treated effectively with antibiot-
ics, making these agents the mainstay of treatment. Given
the role of antibiotics in maintenance therapy, chronic
disease is often categorized by how patients respond to
antibiotic therapy (i.e., antibiotic-responsive, antibiotic-
dependent, or antibiotic-refractory). [2,7] Patients with
antibiotic-dependent pouchitis experience frequent (≥
four episodes per year) or persistent, rapidly relapsing epi-
sodes that respond quickly to antibiotic therapy but recur
soon after discontinuing treatment. Remission mainte-
nance for this type of pouchitis requires long-term, con-
tinuous, low-dose antibiotic therapy or frequent full-dose
antibiotic pulse therapy. [1-3,11-13] Because long-term or
frequent antibiotic therapy can be associated with antibi-
otic resistance and increased adverse effects with pro-
longed administration, safely maintaining remission in
antibiotic-dependent pouchitis can be challenging. [1]
Rifaximin is an oral, broad-spectrum antibiotic with low
systemic absorption (<0.4%) that provides high bioavail-
ability in the gastrointestinal tract with minimal risk of
systemic adverse effects. During the nearly 20 years rifax-
imin has been available in Europe, no clinically signifi-
cant antibiotic resistance has been observed. [14,15] For
patients with chronic refractory pouchitis, combination
therapy with rifaximin and ciprofloxacin improved pou-
chitis disease activity index (PDAI). [6,16] Treatment with
rifaximin monotherapy also appeared to improve symp-
toms in patients with active pouchitis. [17,18]
Given these encouraging preliminary data on the efficacy
of rifaximin in pouchitis and concerns about antibiotic
resistance and adverse effects with systemic antibiotics,
rifaximin may provide an effective option for patients
with antibiotic-dependent pouchitis. The present open-
labeled, historical cohort study was to investigate the effi-
cacy and safety of rifaximin in maintaining remission in
patients with antibiotic-dependent pouchitis.
Methods
Patients
This was a historical cohort study. Eligible patients (≥ 18
years of age) with antibiotic-dependent pouchitis were
seen in our Pouchitis Clinic between July 2004 and June
2006. As a part of standard of practice, clinical, endo-
scopic, and histologic data for all patients were entered
into the Pouchitis Registry, which was approved by the
Institutional Review Board at Cleveland Clinic. Informed
consent was provided by all patients.
Inclusion and exclusion criteria
Patients were required to meet all of the following inclu-
sion criteria: diagnosis of antibiotic-dependent pouchitis,
defined as ≥ four episodes per year, each of which
responded to a 2-week course of ciprofloxacin or metron-
idazole but recurred soon after treatment ended; frequent
episodes of pouchitis requiring long-term (at least 16
weeks), continuous, low-dose antibiotics or frequent
pulse therapy with antibiotics for remission maintenance;
and currently symptomatic. Patients were excluded from
the study if they had antibiotic-refractory pouchitis (i.e.,
unresponsive to a 2–4 week course of ciprofloxacin or
metronidazole); concurrent cuffitis, irritable pouch syn-
drome, or Crohn's disease of the pouch; or a prior history
of adverse reactions to rifaximin.
Treatment
Management of patients with pouchitis followed an algo-
rithm established for Pouchitis Clinic. The management
algorithm was previously published (Figure 1). All
patients suspected of having pouchitis underwent clinical
evaluation and pouch endoscopy. Symptoms and pouch
inflammation were graded using the modified pouchitis
disease activity index (mPDAI),[19] which consisted of
the symptom (range, 0–6) and endoscopy (range, 0–6)
scales from the PDAI. [20] Active pouchitis was defined as
mPDAI score >5 points. [19] Patients who had been rou-
tinely taking non-steroidal anti-inflammatory drugs
(NSAIDs) were asked to discontinue use of these agents
for the duration of the study. However, we did not hold
the initiation of the antibiotic therapy for induction to
allow for wash-out of NSAID use.
To induce remission, patients received single or combina-
tion therapy with ciprofloxacin (1000 mg/day), metroni-
dazole (1000 or 1500 mg/day), tinidazole (1000 mg/
day), or rifaximin (600, 800, or 1200 mg/day) for 2
weeks. The use of single vs. combination therapy to
induce the remission was at the discretion of the treating
physician, based on the pattern of patient's prior response
to the antibiotic therapy. After the induction period, a
repeat pouch endoscopy was performed, and mPDAI
scores were determined. Patients who exhibited symp-
toms or endoscopic signs of pouchitis with mPDAI scores
> 5 points were excluded from the maintenance phase of
the study; only patients in symptomatic and endoscopic
remission began maintenance therapy.
During the maintenance period, all patients received rifax-
imin at a starting dose of 200 mg/day. As a part of stand-
ard care of practice, the patients were followed up inBMC Gastroenterology 2008, 8:26 http://www.biomedcentral.com/1471-230X/8/26
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Pouchitis Clinic or contacted via e-mail or telephone
every 1–3 months during maintenance (for up to 24
months) to assess symptoms and adverse events and to
confirm treatment compliance. Doses of rifaximin were
increased (up to 1800 mg/day) for patients who exhibited
partial response to maintenance therapy. Treatment was
discontinued for patients who were unable to maintain
remission with dose escalation or who chose to discon-
tinue therapy. For patients who failed to maintain remis-
sion or who chose to discontinue therapy before the end
of the 24-month study period, mPDAI symptom scores
were documented at the time of discontinuation, and
repeat endoscopy was conducted, if possible.
Primary and secondary endpoints
The primary efficacy endpoint was the number of patients
who maintained symptomatic remission for 3 months, as
determined by mPDAI symptom scores. Patients who had
not maintained remission or exhibited partial response
were allowed to continue maintenance therapy beyond
the 3-month maintenance assessment. Secondary meas-
ures included symptom response to induction therapy,
the ability to predict remission maintenance based on
clinical factors, and adverse events.
Statistical analyses
Wilcoxon rank sum, chi-square, or Fisher exact tests were
conducted to assess differences between patients who
maintained remission for 3 months and those who did
not maintain remission for 3 months. Within-group dif-
ferences between baseline, post-induction, and post-
maintenance symptom and endoscopy scores were ana-
lyzed using Wilcoxon signed rank tests. Associations
between clinical factors and the primary endpoint (remis-
sion maintenance at 3 months) were calculated using a
multivariate log-binomial model.
Results
A total of 53 patients with antibiotic-dependent pouchitis
were treated with induction therapy with antibiotic mon-
otherapy or combination therapy. Fifty-one patients
achieved symptomatic and endoscopic remission during
the 2-week induction period and began maintenance ther-
apy with rifaximin. The overall median duration of main-
tenance therapy was 8 months (range, 0.5–24 months),
and the overall median maintenance dose was 200 mg/
day (range, 200–1800 mg/day). Following maintenance
therapy with rifaximin, endoscopy scores were obtained
for 30 (60%) of the 51 patients.
Remission maintenance
Of the 51 patients who began maintenance therapy, 33
(65%) were still in remission at the 3-month maintenance
assessment, and 18 (35%) had relapsed within 3 months.
Demographic and clinical characteristics, including age,
sex, extent and duration of UC, duration of IPAA, type of
pouch, IPAA stage, indication for colectomy, family his-
tory of inflammatory bowel disease, smoking, excessive
use of alcohol, weekly NSAID use before beginning the
study were similar for patients who maintained remission
for 3 months and those who relapsed by the 3-month
time point (Table 1).
As expected, patients who maintained remission for 3
months showed no symptomatic or endoscopic evidence
of relapse between the end of induction and the 3-month
maintenance assessment (median change 0 points on
each PDAI scale; Table 2). For patients who relapsed
within 3 months, significant increases in both symptom
and endoscopy scores were observed between the end of
induction and the 3-month maintenance assessment
(median increase of three points on each scale; P  <
0.0005).
The median total duration of maintenance therapy for
patients who were in remission at the 3-month assess-
ment was 12 months, measured from the beginning of
maintenance therapy (Table 1). Of the 33 patients who
were in remission at the 3-month time point, 26 (79%)
continued therapy for 6 months after beginning mainte-
nance, 19 (58%) for 12 months, five (15%) for 18
months, and two (6%) for at least 24 months. Of the 33
patients, 4 had had symptom recurrence sometime
between months 3 and 12. Throughout the total mainte-
nance period, the majority of these 33 patients (23 [70%])
received 200 mg/day of rifaximin, whereas 10 patients
required dose escalation to 400 mg/day (n = 3), 600 mg/
day (n = 3), 800 mg/day (n = 2), 1200 mg/day (n = 1), or
Classification and Treatment Algorithm (Modified from Yu  ED, Shao Z, Shen, B. World J Gastroenterol 2007;13(42):  5598–5604) Figure 1
Classification and Treatment Algorithm (Modified from Yu 
ED, Shao Z, Shen, B. World J Gastroenterol 2007;13(42): 
5598–5604).
Pouchitis Pouchitis
Ciprofloxacin or Metronidazole x 2 wks Ciprofloxacin or Metronidazole x 2 wks
Antx-responsive 
Pouchitis
Antx-responsive 
Pouchitis
Responded Responded Not Responded Not Responded
Ciprofloxacin or metronidazole x 2 more wks Ciprofloxacin or metronidazole x 2 more wks
Responded Responded Not Responded Not Responded
Frequent 
Relapse  
Frequent 
Relapse  
Infrequent 
Relapse
Infrequent 
Relapse
Antx-dependent
Pouchitis
Antx-dependent
Pouchitis
Antx-refractory
Pouchitis
Antx-refractory
Pouchitis
Antibiotics prn Antibiotics prn Probiotics or 
Low-dose 
antibiotics
Probiotics or 
Low-dose 
antibiotics
Cipro+ Metronidazole or 
Rifaximin or Tinidazole x 4 wks
Cipro+ Metronidazole or 
Rifaximin or Tinidazole x 4 wks
5-ASA/Immunomodulators
Steroids/biologic therapy?
5-ASA/Immunomodulators
Steroids/biologic therapy?
Not Responded Not Responded
Exclusion of 
secondary 
causes
Exclusion of 
secondary 
causes
Figure 1. Classification and Treatment Algorithm.  
Modified from Yu ED, Shao Z, Shen, B. World J Gastroenterol 2007;13(42): 5598-5604
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1800 mg/day (n = 1). In addition, 27 (82%) of the 33
patients who maintained remission for 3 months had
received monotherapy during remission induction (Table
1).
As expected, patients who relapsed within 3 months expe-
rienced a shorter duration of maintenance than those who
maintained remission (median 1.3 months vs. 12
months;  P  < 0.001; Table 1); 13 (72%) discontinued
maintenance therapy within 2 months. Patients who
relapsed within 3 months had received a median dose of
200 mg/day of rifaximin, a dose similar to that received by
patients who maintained remission through 3 months.
Eleven (61%) of the patients who relapsed within 3
months had received 200 mg/day of rifaximin, and seven
required dose escalation to 400 mg/day (n = 3), 600 mg/
day (n = 3), or 1200 mg/day (n = 1) during the total main-
tenance period. Significantly fewer patients (8 [44%])
who relapsed within 3 months had received monotherapy
during the remission induction period compared with
patients who maintained remission at 3 months (P  =
0.006; Table 1).
Secondary assessments
Symptom response to induction therapy
To determine if patients who maintained remission for 3
months responded differently to the initial 2-week induc-
tion therapy than those patients who relapsed within 3
months, symptom improvements from baseline to the
end of induction were compared. At baseline, symptom
scores were the same between responders and non-
responders (Table 2). As expected, both patient groups
experienced significant symptom improvement from
baseline to the end of the induction period (median
decrease in mPDAI of three points vs. baseline for each
group;  P  < 0.0001), with no significant differences
between the two patient groups (P = 0.18).
Predictors for maintaining remission
Twenty-two variables were analyzed for their ability to
predict the efficacy of rifaximin for maintaining remis-
sion. Although patients who received antibiotic mono-
therapy during induction were more likely to maintain
remission for 3 months, regression analysis indicated that
antibiotic monotherapy during induction was not predic-
tive of maintaining remission for 3 months (Table 3).
None of the other variables analyzed, including symptom
scores at the end of induction, baseline mPDAI scores,
induction doses of antibiotics, and maintenance doses of
rifaximin, were predictive of maintaining remission with
rifaximin.
Table 1: Demographic and background characteristics
Remission at 3 months (n = 33) Relapse at 3 months (n = 18) P-value
Age, yrs 46.0 47.5 0.6
Male:female, n 18:15 7:11 0.29
Duration of UC, yrs 14.0 12.0 0.79
Type of UC, n (%)
Pancolitis 31 (94) 16 (89) 0.61
Left-sided colitis 2 (6) 2 (11)
Stage IPAA, n (%) 0.29
1 0 (0) 1 (6)
2 25 (76) 15 (83)
3 4 (12) 2 (11)
4 4 (12) 0
Duration of IPAA, yrs 5.0 6.5 0.4
J-type pouch, n (%) 31 (94) 17 (94) 0.99
Family history of IBD, n (%) 7 (21) 5 (28) 0.73
Indication for refractory colectomy, n (%) 23 (70) 17 (94) 0.072
Smoking, n (%) 6 (18) 2 (11) 0.70
Excessive alcohol consumption,* n (%) 3 (9) 0 0.54
Prior weekly NSAID use, n (%) 5 (15) 7 (39) 0.085
Median rifaximin maintenance dose at 3-month assessment, mg/d 
(range)
200 (200–1800) 200 (200–1200)† 0.7
Median duration of maintenance therapy, mo (range) 12 (2–24) 1.3 (0.5–4) < 0.001
Induction therapy, n (%)
Monotherapy 27 (82) 8 (44) NA
Combination therapy 6 (18) 10 (56) 0.006
IBD, inflammatory bowel disease; IPAA, ileal pouch anal anastomosis; NA, not available; NSAID, nonsteroidal anti-inflammatory drug; UC, ulcerative 
colitis.
*Excessive alcohol use defined as more than one drink per day.
†Five of 18 patients who relapsed by 3 months were receiving rifaximin at the 3-month assessment.BMC Gastroenterology 2008, 8:26 http://www.biomedcentral.com/1471-230X/8/26
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Adverse Effects
Rifaximin was well tolerated when administered for up to
24 months. Only one patient discontinued because of an
adverse event (transient facial rash) during maintenance
therapy with rifaximin 200 mg/day; this patient discontin-
ued therapy 2 weeks after beginning maintenance.
Discussion
This open-label study investigated the efficacy of rifaximin
(200–1800 mg/day) in maintaining remission in patients
with antibiotic-dependent pouchitis. The majority (65%)
of patients maintained remission for at least 3 months
with rifaximin, indicated by a lack of increase in mPDAI
symptom scores. The efficacy of rifaximin in maintaining
symptom remission appears encouraging.
Management of antibiotic-dependent pouchitis can be
challenging. Because symptoms quickly recur following
discontinuation of antibiotic treatments, long-term anti-
biotic maintenance therapy is often required. Given the
potential safety concerns associated with long-term ther-
apy with systemic antibiotics frequently administered for
remission maintenance, probiotics have been investigated
as antibiotic-sparing agents for maintaining remission in
patients with chronic or antibiotic-dependent pouchitis.
[11,21,22] Randomized, double-blind trials in Europe
showed that VSL#3®, a lyophilized bacteria product con-
taining four strains of Lactobacillus, three species of Bifido-
bacterium, and Streptococcus salivarius subspecies
Thermophillus, effectively maintained remission for the
majority of patients with chronic or recurrent pouchitis.
[21,22] However, in an open-label, post-marketing study
of VSL#3 in patients with antibiotic-dependent pouchitis
which was conducted by our group, only 19% of patients
remained on the agents at the end of 8-month trial. [11]
These findings suggest that there are barriers in routine use
probiotics in this patient population (such as efficacy,
concerns of exacerbating symptoms, and cost) and alter-
native agents are needed for maintenance therapy of anti-
biotic-dependent pouchitis, particularly in the US patient
population.
The present open-labeled study showed that long-term
maintenance with rifaximin appeared to be effective in
patients with antibiotic-dependent pouchitis, which
would provide useful information for our future design of
randomized trials. (RVIEWER2 Q2) In contrast, a small
randomized trial of oral rifaximin 1200 mg/day vs. pla-
cebo (N = 18) showed a marginal therapeutic benefit in
treating active pouchitis. [23] The dosage of rifaximin
(1200 mg/day) in the study may be too low for treatment
of active pouchitis. There are few studies published to date
which have examined the efficacy of rifaximin in treating
chronic pouchitis. Two studies demonstrated the efficacy
of combination therapy with rifaximin and ciprofloxacin
on PDAI in patients with chronic antibiotic-refractory
Table 2: Symptom and endoscopy scores
Parameter Remission at 3 months (n = 33) Relapse at 3 months (n = 18) P-value
Symptom scores*
Baseline 4 (3, 4) 4 (3, 4) 0.77
Baseline to end of induction 3 (2, 4)† 3 (2, 3)† 0.18
End of induction to 3-month maintenance assessment 0 -3 (-3, -2)† < 0.001
Baseline to 3-month maintenance assessment 3 (2, 4)‡ 0<  0 . 0 0 1
Endoscopy scores*
Baseline 3 (2, 3) 3.5 (3, 5) 0.002
Baseline to end of induction 2 (2, 3)† 3.0 (2, 4)† 0.098
End of induction to 3-month maintenance assessment 0 -3 (-4, -2)§ < 0.001
Baseline to 3-month maintenance assessment 2.5 (2, 3)‡ 1 (0, 1) < 0.001
*Median (25th, 75th percentiles).
†P < 0.0001 within-group change.
‡Significant within-group change.
§P < 0.0005 within-group change.
Table 3: Associations between clinical factors and maintenance efficacy
Reference RR (95% CI) P-value
Induction therapy Single vs. combination therapy 1.67 (0.79–3.49) 0.18
Symptom score after induction 1-unit decrease 1.43 (0.94–2.17) 0.09
Maintenance dose of rifaximin 200-mg/d increase 1.00 (0.87–1.15) 0.97
CI, confidence interval; RR, relative risk.BMC Gastroenterology 2008, 8:26 http://www.biomedcentral.com/1471-230X/8/26
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pouchitis. [6,16] However, patients in these studies
received treatment for only 2 weeks, and efficacy assess-
ments were conducted at the end of treatment to deter-
mine the efficacy of rifaximin in inducing remission.
Although the study by Abdelrazeq et al. [16] included
long-term follow-up assessments for pouch failure with
pouch diversion or excision, neither of these studies eval-
uated the efficacy of rifaximin as long-term maintenance
therapy. A more recent study (presented in abstract form)
in 16 patients with antibiotic- and probiotic-refractory
pouchitis demonstrated that 81% of patients achieved
symptom remission with rifaximin (600–800 mg/day).
[18] The present study extends these findings by demon-
strating that rifaximin appeared to be effective for main-
taining remission.
Because antibiotic-dependent pouchitis requires long-
term, often continuous antibiotic therapy, maintenance
treatment and clinical assessments in the present study
were extended up to 24 months. Patients were treated
with rifaximin as long as they were in remission or until
they chose to discontinue therapy. A high percentage
(58%) of responsive patients were still on maintenance
therapy 12 months after beginning therapy with rifax-
imin, with two patients continuing maintenance therapy
for at least 24 months. These data suggest that rifaximin
effectively maintains remission during long-term therapy,
extending previous findings. [18]
In addition to being efficacious, long-term treatment with
rifaximin was well tolerated. Only one patient reported an
adverse event with transient facial rash. The low incidence
of adverse events reported in this study is consistent with
a 2-week controlled trial for travelers' diarrhea in which
rifaximin (up to 600 mg/day) exhibited a safety profile
similar to that of placebo, as well as with a 4-month,
open-label pouchitis trial with rifaximin (up to 800 mg/
day) during which no adverse events were reported.
[18,24]
The present study had several limitations, including the
open-label historical cohort design, lack of standardized
doses of rifaximin throughout treatment, and incomplete
endoscopy data for 21 of the 51 patients, a short duration
of follow-up (3 month as primary end-point), and loss of
follow-up of some patients after 3 months. (RVIEWER2
Q2) Although, in our experience, the dosage required for
maintaining remission varied, it is possible that relapse of
pouchitis in some patients might result from under-dos-
ing. We chose to start the agent for maintenance therapy
with a small dose for its cost and potential risk for bacte-
rial resistance after long-term use. A dose ranging study is
warranted for both induction and remission for pouchitis.
In addition, the follow-up was set at 3 months after begin-
ning maintenance therapy, although patients could con-
tinue maintenance therapy with rifaximin up to 24
months. While construction of Kaplan-Meier curves and
estimation of recurrence rates would have been a great
addition to this analysis, we unfortunately did not have
the information necessary to do time-to-event analysis. In
this study, recurrence of symptoms was assessed exactly 3
months after induction therapy for all patients and the
exact time of recurrence was not available. Further investi-
gations with prolonged follow-up are needed to more
adequately determine the efficacy of rifaximin for main-
taining endoscopy remission and for maintenance ther-
apy beyond 3 months.
Conclusion
Patients' response to rifaximin as a maintenance therapy
appears to be favorable in this open-labeled trial of anti-
biotic-dependent pouchitis. Randomized, placebo-con-
trolled trials with a longer follow-up are warranted.
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